Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company headquartered in Norwood, Massachusetts, focused on developing therapies for oncology and obesity. Its lead oncology asset, sutantatug envedotin (CRB-701), is a next-generation antibody-drug conjugate targeting Nectin-4-expressing solid tumors, including oropharyngeal squamous cell carcinoma and cervical cancer. The company's other advanced program, CRB-913, is an orally delivered, peripherally restricted CB1 receptor inverse agonist being developed for obesity. Because the company is pre-revenue, investors follow the stock primarily for clinical data readouts, regulatory milestones, and the strength of its balance sheet.
Over the trailing 30 days, CRBP shares declined approximately 49%, moving from a closing level of about $4.29 on October 21, 2026, to an intraday price near $2.19 on November 20, 2026. The decline was broad-based rather than isolated to a single session, with the stock grinding lower through much of the period. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The longer-term picture is more pronounced. Roughly three months earlier, on August 21, 2026, the stock closed near $10.38, meaning the shares have fallen about 79% over the trailing quarter. This sustained downtrend reflects a combination of sector-wide risk aversion in small-cap clinical-stage biotech, financing-related dilution, and a quarterly earnings report that fell short of expectations.
The most significant catalyst during the period was the company's third-quarter 2026 financial results, reported on November 10, 2026. Corbus posted a net loss of approximately $37.8 million, or $1.81 per share, missing consensus estimates near $1.27 per share, and reported no revenue for the quarter. Operating expenses rose to roughly $38.8 million, up from about $24.4 million a year earlier, driven in part by a $15.0 million development milestone paid under the CSPC licensing agreement for sutantatug envedotin.
Financing and dilution concerns also contributed. The company has an at-the-market offering arrangement with Jefferies under which it may sell shares up to $127.5 million, and its outstanding share count increased from about 17.6 million at the end of 2025 to approximately 20.6 million by September 30, 2026. This incremental dilution, combined with a risk-off tone across the biotech sector, pressured the stock.
Analyst activity reflected a more cautious near-term stance. Wedbush lowered its price target to $27 from $30 while maintaining an Outperform rating, and Mizuho reduced its target to $23 from $24 with an Outperform rating. H.C. Wainwright reiterated a Buy rating with a $35 target, and RBC Capital maintained a Buy rating with a $33 target. Partially offsetting the negativity, Corbus announced positive topline data from the CanyON-1 study of CRB-913, which showed statistically significant weight loss with the 60 mg dose at 12 weeks.
The trailing quarter tells a broader story of re-rating across clinical-stage biotech. Entering the period near $10.38, CRBP benefited from positive Phase 1/2 data for CRB-701 presented at the 2026 ASCO annual meeting and the launch of the Phase 3 TEMPO-1 registrational study in oropharyngeal cancer. Over subsequent weeks, however, rising Treasury yields and a broader rotation away from unprofitable small-cap names accelerated selling pressure.
The overhang of the at-the-market financing facility, quant-fund position reductions, and the eventual third-quarter earnings miss reinforced the downward trend. Institutional filings indicated that some systematic investors, including Renaissance Technologies and Millennium Management, trimmed positions during the second quarter. Despite the decline, the company ended the quarter with approximately $115.3 million in cash and investments, which management expects to fund operations into 2028.
Looking ahead, the key variables for CRBP include clinical and regulatory milestones across both lead programs. For CRB-701, investors are monitoring enrollment progress in the TEMPO-1 registrational study and an anticipated exploratory readout from the combination arm with pembrolizumab in first-line oropharyngeal cancer during early 2027. For CRB-913, the company plans to engage with the FDA on its development strategy and is evaluating potential combinations with GLP-1 therapies following the positive CanyON-1 results.
Financial factors also remain important. Additional milestone payments under the CSPC agreement, the pace of clinical spending, and the timing and terms of any future capital raises will influence the shares. Analysts currently maintain a consensus Buy/Outperform posture with price targets well above the recent trading range, but near-term execution risks and broader biotech market sentiment will continue to shape price action. Investors should weigh these catalysts alongside the company's stated cash runway into 2028.
In tracking names like CRBP, I’ve found Tickeron’s AI Daily Buy/Sell Signals particularly useful for spotting shifts in momentum and comparing signals across biotech peers. The platform’s automated approaches help highlight potential entry or exit points based on historical patterns without replacing fundamental analysis. This has become a regular part of my workflow when evaluating volatile clinical-stage companies.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for CRBP entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 287 similar instances where the Aroon Indicator formed such a pattern. In 262 of the 287 cases the stock moved lower. This puts the odds of a downward move at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CRBP just turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 33 of 44 cases over the following month. The odds of a continued upward trend are 75%.
Following a +13.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 226 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.581) is normal, around the industry mean (3.596). P/E Ratio (-0.502) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of drug development services
Industry Biotechnology